Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""progression-free survival"" wg kryterium: Temat


Tytuł :
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
Autorzy :
Chen H; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Qin Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Yang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Liu P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhang C; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
He X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhou S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Yang S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Gui L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Zhou L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Sun Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2847-2857. Date of Electronic Publication: 2020 Jul 25.
Typ publikacji :
Journal Article
MeSH Terms :
Progression-Free Survival*
Leukemia-Lymphoma, Adult T-Cell/*diagnostic imaging
Leukemia-Lymphoma, Adult T-Cell/*mortality
Adolescent ; Adult ; Biomarkers ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate/trends ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Mitotic Index and Progression-Free Survival in Atypical Meningiomas.
Autorzy :
Domingo RA; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Tripathi S; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Vivas-Buitrago T; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Lu VM; Neurologic Surgery Department, Mayo Clinic, Rochester, Minnesota, USA.
Chaichana KL; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Quiñones-Hinojosa A; Neurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: .
Pokaż więcej
Źródło :
World neurosurgery [World Neurosurg] 2020 Oct; Vol. 142, pp. 191-196. Date of Electronic Publication: 2020 Jun 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Progression-Free Survival*
Meningeal Neoplasms/*genetics
Meningioma/*genetics
Mitotic Index/*methods
Humans ; Meningeal Neoplasms/pathology ; Meningeal Neoplasms/surgery ; Meningioma/pathology ; Meningioma/surgery
Czasopismo naukowe
Tytuł :
Progression-free survival in the ICON8 trial.
Autorzy :
Ludmir EB; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
McCaw ZR; Google, Mountain View, CA, USA.
Fuller CD; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei LJ; Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA 02115, USA. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Sep 12; Vol. 396 (10253), pp. 756.
Typ publikacji :
Letter; Comment
MeSH Terms :
Carcinoma*
Progression-Free Survival*
Antineoplastic Combined Chemotherapy Protocols ; Fallopian Tubes ; Female ; Humans
Opinia redakcyjna
Tytuł :
Progression-free survival in the ICON8 trial.
Autorzy :
Balieiro Anastacio da Costa AA; Department of Medical Oncology, A C Camargo Cancer Center, São Paulo 01525-001, Brazil. Electronic address: .
Baiocchi G; Department of Gynecologic Oncology, A C Camargo Cancer Center, São Paulo 01525-001, Brazil.
Guimarães APG; Department of Medical Oncology, A C Camargo Cancer Center, São Paulo 01525-001, Brazil.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Sep 12; Vol. 396 (10253), pp. 756-757.
Typ publikacji :
Letter; Comment
MeSH Terms :
Carcinoma*
Progression-Free Survival*
Antineoplastic Combined Chemotherapy Protocols ; Fallopian Tubes ; Female ; Humans
Opinia redakcyjna
Tytuł :
Progression-free survival in the ICON8 trial - Authors' reply.
Autorzy :
James EC; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK. Electronic address: .
McNeish IA; Department of Surgery and Cancer, Imperial College London, London, UK.
Cook AD; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK.
Kaplan R; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK.
Clamp AR; Department of Medical Oncology, The Christie National Health Service Foundation Trust and University of Manchester, Manchester, UK.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Sep 12; Vol. 396 (10253), pp. 757.
Typ publikacji :
Letter; Comment
MeSH Terms :
Progression-Free Survival*
Disease-Free Survival
Opinia redakcyjna
Tytuł :
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period.
Autorzy :
Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece. .
Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Roussou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Kanellias N; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Fotiou D; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Migkou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Eleutherakis-Papaiakovou E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Gavriatopoulou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528, Athens, Greece.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Jun; Vol. 99 (6), pp. 1257-1264. Date of Electronic Publication: 2020 May 07.
Typ publikacji :
Journal Article
MeSH Terms :
Progression-Free Survival*
Antineoplastic Agents/*therapeutic use
Multiple Myeloma/*diagnosis
Multiple Myeloma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Time Factors
Czasopismo naukowe
Tytuł :
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.
Autorzy :
Hirai T; Teikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku, Tokyo, Japan.; Clinical Development Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.
Nemoto A; Teikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku, Tokyo, Japan.
Ito Y; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Matsuura M; Teikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku, Tokyo, Japan. .; Division of Cancer Genomics, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. .
Pokaż więcej
Źródło :
Breast cancer research and treatment [Breast Cancer Res Treat] 2020 May; Vol. 181 (1), pp. 189-198. Date of Electronic Publication: 2020 Apr 03.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Biomarkers*
Progression-Free Survival*
Triple Negative Breast Neoplasms/*mortality
Triple Negative Breast Neoplasms/*pathology
Disease Progression ; Female ; Humans ; Survival Rate
Czasopismo naukowe
Tytuł :
Microvascular Impairment After Myocardial Infarction: It Is Not Just About Obstruction.
Autorzy :
Lindner JR; Knight Cardiovascular Institute, the Oregon National Primate Research Center, Oregon Health and Science University, Portland.
Pokaż więcej
Źródło :
Circulation. Cardiovascular imaging [Circ Cardiovasc Imaging] 2020 Jun; Vol. 13 (6), pp. e011083. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Editorial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Comment
MeSH Terms :
Myocardial Infarction*/diagnostic imaging
Progression-Free Survival*
Coronary Circulation ; Humans
Raport
Tytuł :
Informative censoring - a neglected cause of bias in oncology trials.
Autorzy :
Templeton AJ; Department of Oncology, St. Claraspital Basel, University of Basel, Basel, Switzerland.; Faculty of Medicine, University of Basel, Basel, Switzerland.
Amir E; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Tannock IF; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. .
Pokaż więcej
Źródło :
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2020 Jun; Vol. 17 (6), pp. 327-328.
Typ publikacji :
Journal Article
MeSH Terms :
Bias*
Progression-Free Survival*
Survival Rate*
Neoplasms/*therapy
Humans ; Intention to Treat Analysis ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.
Autorzy :
Stewart DJ; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Bossé D; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Goss G; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Hilton JF; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Jonker D; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Fung-Kee-Fung M; University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. Electronic address: .
Pokaż więcej
Źródło :
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2020 Apr; Vol. 148, pp. 102896. Date of Electronic Publication: 2020 Feb 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Disease-Free Survival*
Progression-Free Survival*
Randomized Controlled Trials as Topic*
Antineoplastic Agents/*therapeutic use
Neoplasms/*mortality
Disease Progression ; Humans ; Medical Oncology ; Neoplasm Recurrence, Local/mortality ; Neoplasms/drug therapy ; Neoplasms/pathology ; Proportional Hazards Models ; Survival Analysis
Czasopismo naukowe
Tytuł :
ASO Author Reflections: Effect of Primary Surgery on Quality of Life in De Novo Stage IV Breast Cancer Patients.
Autorzy :
Si Y; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuan P; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. .
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2020 Apr; Vol. 27 (4), pp. 1034-1035. Date of Electronic Publication: 2020 Feb 07.
Typ publikacji :
Journal Article
MeSH Terms :
Progression-Free Survival*
Quality of Life*
Breast Neoplasms/*surgery
Mastectomy/*methods
Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; China/epidemiology ; Female ; Humans ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Targeting fusions for improved outcomes in oncology treatment.
Autorzy :
Nikanjam M; Division of Hematology and Oncology, Center for Personalized Cancer Therapy, Moores Cancer Center, University of California at San Diego, San Diego, California.
Okamura R; Division of Hematology and Oncology, Center for Personalized Cancer Therapy, Moores Cancer Center, University of California at San Diego, San Diego, California.
Barkauskas DA; Biostatistics Division, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Kurzrock R; Division of Hematology and Oncology, Center for Personalized Cancer Therapy, Moores Cancer Center, University of California at San Diego, San Diego, California.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Mar 15; Vol. 126 (6), pp. 1315-1321. Date of Electronic Publication: 2019 Dec 03.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Progression-Free Survival*
Molecular Targeted Therapy/*methods
Neoplasms/*drug therapy
Neoplasms/*genetics
Oncogene Proteins, Fusion/*genetics
California ; Drug Approval/statistics & numerical data ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/genetics ; Humans ; Kaplan-Meier Estimate ; Odds Ratio ; Treatment Outcome ; United States
Czasopismo naukowe
Tytuł :
Inappropriate use of progression-free survival in cancer drug approvals.
Autorzy :
Naci H; Department of Health Policy, London School of Economics and Political Science, London, UK .
Davis C; Department of Global Health and Social Medicine, King's College London, London, UK.
Pokaż więcej
Źródło :
BMJ (Clinical research ed.) [BMJ] 2020 Mar 10; Vol. 368, pp. m770. Date of Electronic Publication: 2020 Mar 10.
Typ publikacji :
Editorial
MeSH Terms :
Drug Approval*
Progression-Free Survival*
Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
United States Food and Drug Administration/*standards
Humans ; Quality of Life ; Survival Analysis ; United States
Opinia redakcyjna
Tytuł :
Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality.
Autorzy :
Mistretta FA; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. .; Department of Urology, European Institute of Oncology, Milan, Italy. .
Palumbo C; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
Knipper S; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.; Martini-Klinik, Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Mazzone E; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Pecoraro A; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.; Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
Tian Z; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Musi G; Department of Urology, European Institute of Oncology, Milan, Italy.
Perrotte P; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.
Montanari E; Department of Urology, IRCCS Fondazione Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Shariat SF; Department of Urology, Medical University of Vienna, Vienna, Austria.
Saad F; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.
Briganti A; Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
de Cobelli O; Department of Urology, European Institute of Oncology, Milan, Italy.; Dipartimento di Emato-Oncologia ed Oncologia, University of Milan, Milan, Italy.
Karakiewicz PI; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.
Pokaż więcej
Źródło :
World journal of urology [World J Urol] 2020 Mar; Vol. 38 (3), pp. 725-732. Date of Electronic Publication: 2019 Jul 11.
Typ publikacji :
Journal Article
MeSH Terms :
Cause of Death*
Progression-Free Survival*
Carcinoma, Squamous Cell/*mortality
Penile Neoplasms/*mortality
Aged ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/surgery ; Humans ; Lymph Node Excision ; Lymph Nodes/pathology ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Penile Neoplasms/pathology ; Penile Neoplasms/surgery ; Proportional Hazards Models ; SEER Program ; Time Factors ; Urologic Surgical Procedures, Male
Czasopismo naukowe
Tytuł :
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.
Autorzy :
Gougis P; Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; Department of Clinical Pharmacology, Centre D'Investigation Clinique Paris-Est, AP-HP, Pitié-Salpêtrière Hospital, PSL University, CLIP² Galilée, Paris, France.
Carton M; Department of Biostatistics, Institut Curie, Saint-Cloud, France.
Tchokothe C; Department of Biostatistics, Institut Curie, Saint-Cloud, France.
Campone M; Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Nantes and Angers, France.
Dalenc F; Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.
Mailliez A; Department of Breast Cancer, Centre Oscar Lambret, Lille, France.
Levy C; Department of Medical Oncology, Centre François Baclesse, Caen, France.
Jacot W; Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier, France.
Debled M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
Leheurteur M; Department of Medical Oncology, Henri Becquerel Centre, Rouen, France.
Bachelot T; Department of Biostatistics, Centre Léon Bérard, Lyon, France.
Hennequin A; Department of Medical Oncology, Center Georges François Leclerc, Dijon, France.
Perrin C; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Uwer L; Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
Eymard JC; Department of Medical Oncology, Centre Jean Godinot, Reims, France.
Petit T; Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.
Mouret-Reynier MA; Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.
Chamorey E; Department of Biostatistics, Centre Antoine Lacassagne, Nice, France.
Simon G; Department of Research and Development, R&D Unicancer, Paris, France.
Saghatchian M; Department of Biostatistics, Institut Curie, Saint-Cloud, France.
Cailliot C; Department of Research and Development, R&D Unicancer, Paris, France.
Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; U900 INSERM Research Unit, Saint-Cloud, France. Electronic address: .
Pokaż więcej
Źródło :
Breast (Edinburgh, Scotland) [Breast] 2020 Feb; Vol. 49, pp. 17-24. Date of Electronic Publication: 2019 Oct 19.
Typ publikacji :
Journal Article
MeSH Terms :
Progression-Free Survival*
Breast Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/metabolism ; Breast Neoplasms/mortality ; Databases, Factual ; Female ; Follow-Up Studies ; France/epidemiology ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Retrospective Studies ; Risk Factors ; Survival Analysis ; Time Factors ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Autorzy :
Levey AO; Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Emory University School of Medicine, Atlanta, USA.
Elsayed M; Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Emory University School of Medicine, Atlanta, USA.
Lawson DH; Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, USA.
Ermentrout RM; Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Emory University School of Medicine, Atlanta, USA.
Kudchadkar RR; Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, USA.
Bercu ZL; Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Emory University School of Medicine, Atlanta, USA.
Yushak ML; Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, USA.
Newsome J; Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Emory University School of Medicine, Atlanta, USA.
Kokabi N; Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Emory University School of Medicine, Atlanta, USA. .
Pokaż więcej
Źródło :
Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2020 Feb; Vol. 43 (2), pp. 254-263. Date of Electronic Publication: 2019 Nov 04.
Typ publikacji :
Journal Article
MeSH Terms :
Progression-Free Survival*
Brachytherapy/*methods
Eye Neoplasms/*pathology
Liver Neoplasms/*radiotherapy
Liver Neoplasms/*secondary
Melanoma/*pathology
Yttrium Radioisotopes/*therapeutic use
Combined Modality Therapy/methods ; Female ; Humans ; Immunotherapy/methods ; Kaplan-Meier Estimate ; Liver Neoplasms/therapy ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Incorporating radiomic feature of pretreatment F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
Autorzy :
Chen, Yu-Hung (AUTHOR)
Wang, Tso-Fu (AUTHOR)
Chu, Sung-Chao (AUTHOR)
Lin, Chih-Bin (AUTHOR)
Wang, Ling-Yi (AUTHOR)
Lue, Kun-Han (AUTHOR)
Liu, Shu-Hsin (AUTHOR)
Chan, Sheng-Chieh (AUTHOR)
Pokaż więcej
Źródło :
PLoS ONE. 12/28/2020, Vol. 15 Issue 12, p1-18. 18p.
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies